{
  "docId": "019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "docSlug": "87d7e2eb7c56e30923dbf29903df5034",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 40,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 8,
  "notes": "The slide compares internal trial data for CTX-009 against historical benchmarks (FOLFOX and TOPAZ-1) to demonstrate efficacy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-dee8-7497-a5f7-ae2745d7f9f6/23",
  "deckHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6",
  "deckJsonHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6.json",
  "deckAnchorHref": "/decks/019de074-dee8-7497-a5f7-ae2745d7f9f6#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.395,
        "x": 0.074,
        "y": 0.335
      },
      "kind": "list",
      "text": "24 patients with BTC have been enrolled and dosed. 9 partial responses (PRs) for a 37.5% ORR in patients treated in the second- and third-line settings (64% ORR of patients treated in the 2nd line setting). Median PFS 9.4 months. Median OS 12.5 months.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "80ee9e4b-1409-4c84-b238-53097397b12c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.395,
        "x": 0.555,
        "y": 0.36
      },
      "kind": "list",
      "text": "FOLFOX (NCCN guidelines): 5% ORR in the second-line setting, 4.0 month median PFS, 6.2 month median OS. TOPAZ-1 (Phase 3 study): 26.7% ORR for Gem/Cis/Durvalumab (anti PD-L1) in the first-line setting",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdc2aa48-a41d-4cb2-a7a4-d68a50347589",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.612,
        "x": 0.046,
        "y": 0.175
      },
      "kind": "title",
      "text": "CTX-009 Interim Phase 2 Study Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f554f0be-a7d6-4dab-9781-e4864331e3ff",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Audience Definition",
      "slug": "audience-definition",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "2458564f-e9ce-4931-9219-89160fde0531",
      "evidence": "list/bullet: 24 patients with BTC have been enrolled and dosed. 9 partial responses (PRs) for a 37.5% ORR in patients treated in the second- and third-line settings (64% ORR of patients treated in the 2nd line setting).",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "9ac9623f-1331-49cb-99e8-b24c48db3c49",
      "evidence": "Side-by-side presentation of internal clinical data vs external benchmarks.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 23,
      "from": 22,
      "name": "Confession",
      "slug": "22-confession",
      "bestFor": "Crisis communication, rebuilding trust, authenticity marketing",
      "matchId": "8482f1fe-537e-401e-ab59-ce88194526d2",
      "evidence": "slides 22-23",
      "position": 1,
      "objective": "Show how CTX-009 data compares to other BTC studies",
      "structure": "The Honest Admission -> What We Learned -> How We're Different Now",
      "confidence": 0.6,
      "description": "Build credibility by admitting a weakness or mistake before presenting your strength"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}